Search

Displaying results 5701 - 5710 of 10000 in total
  1. Drug

    GLPG-1205

    go.drugbank.com/drugs/DB15346
    Investigational

    GLPG-1205 is under investigation in clinical trial NCT03725852 (A Clinical Study to Test How Effective and Safe GLPG1205 is for Patients With Idiopathic Pulmonary Fibrosis (IPF)).

  2. Drug

    ALT-P1

    go.drugbank.com/drugs/DB18485
    Investigational

    ALT-P1 is a long-acting recombinant human growth hormone fused to an alpha1-antitrypsin variant. It is under investigation for the treatment of growth hormone deficiency.

  3. Drug

    Reloxiliase

    go.drugbank.com/drugs/DB17653
    Experimental

    Reloxiliase is a first-in-class, oral crystalline formulation of the oxalate-specific, microbial enzyme oxalate decarboxylase. It is being investigated for the treatment of hyperoxaluria.[A258823]

  4. Drug

    Timbetasin

    go.drugbank.com/drugs/DB19119
    Investigational

    Timbetasin is under investigation in clinical trial NCT05555589 (Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2).

    Synonyms: Ac-ser-asp-lys-pro-asp-met-ala-glu-ile-glu-lys-phe-asp-lys-ser-lys-leu-lys-lys-thr-glu-thr-gln-glu-lys-asn-pro-leu-pro-ser-lys-glu-thr-ile-glu-gln-glu-lys-gln-ala-gly-glu-ser, L-SERINE, N-ACETYL-L-SERYL-L-.ALPHA.-ASPARTYL-L-LYSYL-L-PROLYL-L-.ALPHA.-ASPARTYL-L-METHIONYL-L-ALANYL-L-.ALPHA.-GLUTAMYL-L-ISOLEUCYL-L-.ALPHA.-GLUTAMYL-L-LYSYL-L-PHENYLALANYL-L-.ALPHA.
  5. Drug

    RD13-02

    go.drugbank.com/drugs/DB27110
    Investigational

    RD13-02 is a biologic drug. RD13-02 is under investigation in clinical trial NCT05923541 (RD13-02 for Patients With r/r CD7+ T Cell Hematologic Malignancies).

  6. Drug

    Efonidipine

    go.drugbank.com/drugs/DB09235
    Investigational

    The drug has been shown to block T-type in addition to L-type calcium channels [A7844, A32001]. It has also been studied in atherosclerosis and acute renal failure [A32001]. … Efonidipine is a calcium channel blocker of the _dihydropyridine class_, commercialized by Shionogi & Co. (Japan). Initially, it was marketed in 1995 under the trade name, _Landel_.

  7. Drug

    NVP-LEQ-506

    go.drugbank.com/drugs/DB12857
    Investigational

    LEQ506 has been used in trials studying the treatment of Advanced Solid Tumors, Recurrent or Refractory Medulloblastoma, and Locally Advanced or Metastatic Basal Cell Carcinoma.

  8. Drug

    Cenacitinib

    go.drugbank.com/drugs/DB21735
    Investigational

    Cenacitinib is under investigation in clinical trial NCT05688852 (VTX958 for the Treatment of Moderately to Severely Active Crohn's Disease). … Cenacitinib is a small molecule drug. The usage of the INN stem '-citinib' in the name indicates that Cenacitinib is a Janus kinase inhibitor.

  9. Drug

    Flufenamic acid

    go.drugbank.com/drugs/DB02266
    Approved

    (From Martindale, The Extra Pharmacopoeia, 30th ed, p16) … An anthranilic acid derivative with analgesic, anti-inflammatory, and antipyretic properties. It is used in musculoskeletal and joint disorders and administered by mouth and topically.

  10. Drug

    Allogenic Human Umbilical Derived Mesenchymal Stem Cells in Conditioned Media

    go.drugbank.com/drugs/DB15728
    Experimental

    One of these companies, Aspire, has created their own product, ACT-20 Conditioned Medium as a product for testing. … Umbilical-cord derived MSCs are currently being tested for numerous clinical applications due to their immunosuppressive and anti-inflammatory properties.

    Synonyms: Allogeneic Human Umbilical Derived Mesenchymal Stem Cells in Conditioned Media, Allogenic Human Umbilical Derived Mesenchymal Stem Cells in Conditioned Media